Voyager Therapeutics, Inc. (NASDAQ:VYGR) is a biotechnology company that focuses on developing genetic treatments for neurological diseases. The company operates within the Zacks Medical - Biomedical and Genetics industry. Voyager is working on innovative therapies, including tau-targeting assets for Alzheimer's disease and novel neuro gene therapies. The company is also advancing its NeuroShuttle™ platform, which is supported by promising preclinical studies.
On March 9, 2026, Voyager reported its earnings, revealing an EPS of -$0.46, which fell short of the estimated -$0.40. However, the company reported a revenue of $15.34 million, surpassing the estimated $10 million. This revenue figure exceeded the Zacks Consensus Estimate by 57.97% and marked a significant increase from the $6.28 million reported in the same quarter last year.
Despite the negative EPS, Voyager's quarterly loss of $0.46 per share was better than the Zacks Consensus Estimate of a $0.54 loss. This represents a positive surprise of 15.08%. The company has consistently outperformed expectations, as seen in the previous quarter when it reported a loss of $0.47 per share against an anticipated $0.53 loss, resulting in an 11.32% surprise.
Voyager's financial health is supported by a cash position of $202 million, expected to sustain operations until 2028. The company has a low debt-to-equity ratio of 0.19, indicating a relatively low level of debt compared to its equity. Additionally, Voyager has a strong current ratio of 7.64, suggesting a robust ability to cover its short-term liabilities with its short-term assets.
Voyager's valuation metrics reflect its current financial situation. The company has a price-to-earnings (P/E) ratio of approximately -2.01, indicating negative earnings. The price-to-sales ratio stands at about 5.66, and the enterprise value to sales ratio is approximately 4.95. Despite these challenges, Voyager remains focused on advancing its pipeline and achieving key milestones in 2026.
